Mississippi’s three healthcare licensing boards have put the state’s providers on notice: there is no safe harbor for offering “research-grade” peptides to patients. In a joint statement issued by the Mississippi State Board of Medical Licensure, the Mississippi Board of Nursing, and the Mississippi Board of Pharmacy, the boards made clear that recommending, supplying, prescribing, or administering these unapproved substances is the practice of medicine — and that practice is prohibited when the product hasn’t been through the FDA.
The statement lands amid a broader national reckoning over peptide and compounded GLP-1 products, as manufacturers like Eli Lilly escalate legal action against black-market sellers and regulators nationwide scrutinize the “research use only” label as a liability shield. Mississippi’s boards just closed that door at the state level, and other states are likely to follow with similar guidance.
What the Joint Statement Says
The statement is short, but it is unambiguous. A few key points stand out for practice owners and licensed providers:
- Research-grade peptides carry unknowable risk. Because these products aren’t FDA-regulated, the boards note that neither providers nor patients can verify what’s actually in the vial, or assess the safety and efficacy of what’s being injected.
- There is no workaround. The statement flatly prohibits providers from compounding, administering, or dispensing non-FDA-approved peptides, and closes the obvious loophole: a provider can’t sidestep this duty by delegating the purchase, administration, or dispensing to another provider. Advising, recommending, supplying, prescribing, and administering are all captured.
- Sourcing matters too. Providers are required to purchase all prescription products, drugs, and ingredients from entities licensed by the Mississippi Board of Pharmacy, and the boards point practices toward the Board of Pharmacy’s license verification tool to confirm a supplier is legitimate before ordering.
The Waiver Language Practices Should Read Twice
The section of the statement most relevant to day-to-day operations addresses consent forms, and it’s worth quoting directly:
“A healthcare provider cannot require or permit a patient to ‘waive’ the provider’s duty of care to the patient and the professional’s personal obligation to follow the law. Patient consent forms purporting to identify a product as ‘research-grade’ do not mitigate or eliminate a provider’s professional or legal liability.”
In other words, a well-drafted consent form is not a compliance strategy. Many practices have leaned on “research use only” or “not for human consumption” language in intake paperwork, on the theory that a signed disclosure shifts risk to the patient. Mississippi’s boards are saying that theory doesn’t hold: liability follows the license, not the paperwork. If a provider is involved in getting the product into the patient at all, the waiver doesn’t change what that involvement is.
Where the Line Actually Sits
The statement also draws a clean distinction that’s useful for practices trying to understand where their exposure begins and ends:
“In circumstances where a patient independently acquires and self-administers such substances, the associated risk rests solely with the patient. However, any involvement by a medical professional in recommending, supplying, prescribing, or administering these substances constitutes the practice of medicine and is prohibited.”
Read together, these two passages define the boundary precisely. A patient who orders a peptide on their own and injects it themselves, with zero provider involvement, bears that risk alone — the boards aren’t asserting jurisdiction over what a consumer does in their own kitchen. But the moment a licensed provider touches any part of that transaction — recommending a product, supplying it, writing anything resembling a prescription, or administering it in-office — the activity becomes the practice of medicine, full stop. There is no “research-grade” or “off-label wellness” characterization that moves it back across that line.
What This Means for Practices Operating in Mississippi
For medical spas, IV hydration clinics, and wellness practices with a medical director or supervising provider on staff, this statement should prompt a few concrete steps:
- Audit the menu. Any peptide, compounded product, or “research-use” item currently offered should be checked against FDA approval status and the practice’s Board of Pharmacy-licensed supplier relationships.
- Review consent paperwork. If intake forms include “research-grade” disclosures or waiver language intended to limit liability, those documents need a second look — the boards have now said explicitly that this language doesn’t do what practices may have assumed it does.
- Revisit medical director exposure. Delegation doesn’t create distance. A supervising physician who allows nurse injectors or aestheticians to handle these products retains the same duty of care and the same liability.
- Confirm supplier licensure. Before restocking anything, verify the vendor through the Mississippi Board of Pharmacy’s license search rather than relying on a supplier’s own representations.
The Bigger Picture
This joint statement is consistent with where regulators and manufacturers alike are heading nationally: closing off the “research-grade” and “research-use-only” label as a way to sell unapproved substances into a clinical setting. Labels and disclaimers will not shield a practice from regulatory scrutiny when an unapproved product is being used in a clinical setting. Practices that have built any part of their service menu around this gray area should treat statements like Mississippi’s as a preview of where enforcement is headed in other states, not an isolated, single-state development.
This article is intended for general informational purposes only and does not constitute legal advice. Because the rules governing peptides, compounded products, and related services vary by state and continue to evolve, practices should consult qualified healthcare regulatory counsel regarding their specific operations.
Have questions about your practice’s peptide or compounded-product offerings? Schedule a consultation with the Lengea Law team to evaluate your regulatory exposure and build a compliant path forward.